

This is the peer reviewed version of the following article: Cameron, D., Harris, F. M. and Evans, J. M. M. (2016), Patterns of self-monitoring of blood glucose in insulin-treated diabetes: analysis of a Scottish population over time. *Diabetes, Obesity and Metabolism*, 18: 729–731. doi: 10.1111/dom.1266, which has been published in final form at <http://onlinelibrary.wiley.com/doi/10.1111/dom.12662/abstract>. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

# **Patterns of self-monitoring of blood glucose (SMBG) in insulin-treated diabetes: analysis of a Scottish population over time.**

Dawn Cameron, School of Health Sciences, University of Stirling, Stirling, FK9 4LA.

PhD Student.

Fiona M Harris, Nursing, Midwifery and Allied Health Professionals Research Unit, University of Stirling, FK9 4NF

Senior Lecturer

Josie MM Evans, School of Health Sciences, University of Stirling, Stirling, FK9 4LA.

Reader in Public Health

Corresponding author:

Dawn Cameron

School of Health Sciences

University of Stirling

Stirling

FK9 4LA

Tel no: +44 1786 466352

Fax no: +44 1786 466333

E mail: dawn.cameron@stir.ac.uk

Running title: Self-monitoring of blood glucose in insulin-treated diabetes

## **Abstract**

Analysis of a diabetes clinical information system in Tayside, Scotland, shows that a significant proportion of insulin-treated patients with diabetes are not self-monitoring blood glucose according to current clinical guidance and recommendations, with some not self-monitoring their blood glucose at all. Although there has been an increase in the numbers of reagent strips dispensed over the past decade, this increase is mainly accounted for by increased testing frequency among people with diabetes already testing.

## **Introduction**

Self-monitoring of blood glucose (SMBG) is fundamental to diabetes self-management for people with type 1 diabetes and those with type 2 diabetes treated with insulin (1,2) with an important role to play in the prevention of hypoglycaemia and in the reduction of longer-term complications. Current guidance recommends routine SMBG in type 1 diabetes; at least four times per day and possibly even up to ten times daily, with frequency and timing individualized to the patient (1–3). Guidance for type 2 diabetes suggests that routine testing should be undertaken by people treated with insulin (1,4–6) and anyone at particular risk of hypoglycaemia.

Studies have shown a general increase in self-monitoring over the past two decades in the UK and elsewhere (7,8). Frequency of testing has increased alongside increases in the numbers of those testing. A study in Scotland identified an increase in the proportion of all people with type 2 diabetes carrying out any SMBG from 15.5% in 1993 to 29.8% in 2009 (7). However, it is perhaps more important to assess the level of testing in patient groups for whom regular testing is specifically recommended. We therefore used a record-linkage diabetes clinical information system in Tayside, Scotland, to investigate patterns and levels of self-monitoring among people with type 1 diabetes and those with type 2 diabetes who are treated with insulin.

## **Methods**

The Health Informatics Centre, University of Dundee (9,10) uses the record-linkage of health care data to facilitate epidemiological and health services research in Scotland. Record-linkage is enabled by the widespread use of a unique health care identifier (CHI number) that is allocated to people when they register with a General Practitioner (GP) in Scotland. SCI-DC (Scottish Care Information – Diabetes Collaboration) is a validated population-based diabetes information system, compiled by record-linking several independent data sources [6]. Detailed clinical information is available via SCI-DC for all people with diabetes. There are also computerised records of prescriptions dispensed, including those for self-monitoring equipment to residents of the region of Tayside, (current estimated population is 412,160). These are free of charge so almost everyone with diabetes is likely to obtain their reagent strips via this route.

People in Tayside with either type 1 or type 2 diabetes, who were dispensed at least one prescription of insulin during that year were identified for the period 2004 to 2011. The total numbers of SMBG reagent strips dispensed to them were calculated from information on the prescription. A cross-sectional analysis of a 3 year period 1/1/2009 - 31/12/2011 was also undertaken. We investigated whether SMBG patterns were associated with age, sex and a postcode measure of material deprivation that classified people into quintiles of deprivation (according to information on income, employment, health and disability, education, skills, and training and access to services for small geographical areas) [6]. Proportions testing within sub-groups and the median number of strips dispensed in the 3-year period were also determined.

## **Results**

The overall numbers of SMBG reagent strips dispensed has almost doubled over time, from 833,500 strips dispensed to 1,225 people with type 1 diabetes in 2004, to 1,547,950 strips dispensed to 1,573 people in 2011. Similarly, in type 2 diabetes, numbers of SMBG strips dispensed increased from 950,400 dispensed to 1,830 people treated with insulin in 2004 to 1,416,200 dispensed to 2,473 people in 2011 (Table 1).

The proportion of people with type 1 diabetes who received any strips increased from 72% in 2004 to 80% in 2011, suggesting that there are still around one in five who are not testing at all. The approximate doubling in the number of strips dispensed over time can be attributed almost equally to increased numbers of people testing, and to increased frequency among those already testing (as shown by an increase in the median number of strips dispensed). In contrast, in type 2 diabetes, the proportion who test has remained relatively stable over the study period; 88% in 2004 and 91% in 2011. The large increase in the overall number of strips dispensed is therefore accounted for by increases in testing frequency among those who already test, rather than being an indication of wider engagement with SMBG. Despite this, many people are still not receiving enough strips to test more than once or twice daily, although testing frequency is higher in type 1 diabetes.

Table 2 shows that between 2009 and 2011, women were more likely to test, and people with type 1 diabetes were testing more frequently. There was an effect of deprivation on frequency of testing, with people living in less deprived areas testing more frequently than those living in more deprived areas. In general, testing frequency increased with age but the proportion of older people (70+ years) doing any testing with type 2 diabetes was particularly low.

## **Discussion**

Despite a body of evidence identifying the importance of SMBG in maintaining glycaemic control and in turn decreasing the risk of diabetic related complications (6,10), around 10-20% of people with type 1 and type 2 diabetes who are treated with insulin are not testing at all. This level of non-testing has remained stable over the last decade. Furthermore, testing is not carried out as frequently as recommended within both patient groups. These low levels of testing are worrying given the importance of SMBG in the prevention of hypoglycaemia, and possible implications for behaviours such as driving. There is also evidence that SMBG may be associated with reductions in diabetes-related complications. These findings therefore have significant implications for health costs for individual people and health services. (10–12).

The effect of deprivation on frequency of testing has been noted by several authors, in particular in type 2 diabetes, and is a concern given its potential to widen inequalities in diabetes outcomes (7,13–16). It is important that everyone who is treated with insulin and for whom SMBG may be beneficial has appropriate knowledge surrounding testing recommendations and the practice of self-monitoring (16)..

The strengths of this study are its population-based approach and the use of a validated diabetes clinical information system, with records of *dispensed* prescriptions for reagent strips. However, we cannot be sure that people necessarily used the reagent strips that were dispensed to them; neither can we be sure that some did not receive strips from other sources. The study does identify a need for a deeper understanding of why people are not self-monitoring in line with current guidance. There is a need to investigate further how people are testing and as well as influences on testing behaviours.

## **Competing Interests**

Nothing to declare

## **Acknowledgements**

We acknowledge the Health Informatics Centre, University of Dundee for the provision of data. This study was part funded by Lifescan, Scotland, Ltd, The researchers were independent from the funding body.

## REFERENCES

1. Scottish Intercollegiate Guidelines Network. 116 Management of Diabetes: a national clinical guideline. 2010. <http://www.sign.ac.uk/pdf/sign116.pdf>. Accessed 4/4/2016.
2. Reynolds R., Webb D. Recommendations and conclusions from a mini-symposium on self-blood glucose monitoring. *J R Coll Physicians Edinb*. 2006;36:155–8.
3. National Institute of Health Care and Excellence. Type 1 diabetes in adults : diagnosis and management. NICE Guideline. 2015. <https://www.nice.org.uk/guidance/ng17>. Accessed 4/4/2016.
4. Hansen M V, Pedersen-Bjergaard U, Heller SR, Wallace TM, Rasmussen a K, Jørgensen H V, et al. Frequency and motives of blood glucose self-monitoring in type 1 diabetes. *Diabetes Res Clin Pract*.2009; 85(2):183–8
5. Nomura DM. Importance of using and understanding self-monitoring of blood glucose (SMBG) data in assessing ambient and long-term glycaemic control. *J Indian Med Assoc* [Internet]. Lifescan Inc, California, USA.: Indian Medical Association : Calcutta; 2002;100(7):448.
6. Montagnana M, Caputo M, Giavarina D, Lippi G. Overview on self-monitoring of blood glucose. *Clin Chim Acta*.2009;402(1-2):7–13.
7. Evans JMM, Mackison D, Emslie-Smith A, Lawton J. Self-monitoring of blood glucose in Type 2 diabetes: cross-sectional analyses in 1993, 1999 and 2009. *Diabet Med* 2012; 29,(6):792–5.
8. Pan L, Mukhtar Q, Geiss LS. Self-Monitoring of Blood Glucose Among Adults with Diabetes--United States, 1996-2005. *Diabetes*. 2007 Feb;56:A257–A257.
9. Scottish Government, Using the Scottish Index of Multiple Deprivation, Guidance leaflet, 2006 . <http://www.gov.scot/Publications/2006/10/13142841/1>. Accessed 4/4/2016
10. St John A, Davis W, Price CP, Davis TME. The value of self-monitoring of blood glucose: a review of recent evidence. *J Diabetes Complications*.; 2010;24(2):129–41.
11. O’Kane MJ, Pickup J. Self-monitoring of blood glucose in diabetes: is it worth it? *Ann Clin Biochem*. 2009;46(Pt 4):273–82.
12. Belsey JD, Pittard JB, Rao S, Urdahl H, Jameson K, Dixon T. Self blood glucose monitoring in type 2 diabetes. A financial impact analysis based on UK primary care. *Int J Clin Pract*. 2009;63(3):439–48.
13. Kjome RLS, Granas AG, Nerhus K, Roraas TH, Sandberg S. The Prevalence of Self-Monitoring of Blood Glucose and Costs of Glucometer Strips in a Nationwide Cohort. *Diabetes Technol & Ther*. 2010;12(9):701–5.
14. Secnik K, Yurgin N, Lage MJ, McDonald-Everett C. Patterns of blood glucose monitoring in relation to glycemic control among patients with type 2 diabetes in the UK. *J Diabetes Complications*. 2007;21(3):181–6.
15. Jaworska J, Dziemidok P, Kulik TB, Rudnicka-Drozak E. Frequency of self-monitoring and its effect on metabolic control in patients with type 2 diabetes. *Ann Univ Mariae Curie-Skłodowska Sectio D Med*. 2004;59(1):310–6.

16. Abbott S, Burns J. Community nurses and self-monitoring of blood glucose. *British Journal of Community Nursing*. 2007;12(1).

## **TABLES**



Table 1: Numbers of SMBG reagent strips dispensed by year and the number of patients with any strips dispensed

Year	Type 1 diabetes				Type 2 diabetes			
	No. of patients	No. of strips dispensed	No. (%) of patients with strips dispensed	Median no. of strips dispensed per day <sup>1</sup>	No. of patients	No. of strips dispensed	No. (%) of patients with strips dispensed	Median no. of strips dispensed per day <sup>1</sup>
2004	1698	833500	1225 72%	1.4	2073	950400	1830 88%	1.1
2005	1712	882250	1464 85%	1.2	2125	1096300	1934 91%	1.2
2006	1802	1100200	1376 76%	1.6	2273	1201350	2065 91%	1.2
2007	1845	536000	1207 65%	0.8	2228	1018100	1952 88%	1.1
2008	1882	648450	1179 64%	1.0	2246	1006555	1959 87%	1.1
2009	1951	810900	1337 68%	0.5	2466	1236950	2176 88%	1.2
2010	1946	1432100	1554 80%	1.9	2597	1352100	2337 90%	1.2
2011	1969	1574950	1573 80%	2.2	2718	1416200	2473 91%	1.4
<sup>1</sup> Among patients with any strips dispensed								

Table 2: Numbers of SMBG reagent strips dispensed and numbers of patients receiving strips, stratified by gender, age and deprivation

Attribute	Type 1 diabetes				Type 2 diabetes			
	N	No. of patients	% of patients	Median no. of strips	N	No. of patients	% of patients	Median

		nts with strips dispe nsed	with strips dispensed	dispensed per day <sup>1</sup>		with strips dispensed	with strips dispensed	no. of strips dispensed per day <sup>1</sup>
<b>Gender</b>								
Female	818	738	90%	1.8	941	872	93%	1.0
Male	982	845	86%	1.4	1053	950	90%	1.1
<b>Age</b>								
1 13-24	408	362	89%	1.4	4	4	100%	0.3
2 25-40	539	451	84%	1.1	70	56	80%	0.5
3 41-55	545	483	89%	1.6	377	338	90%	0.7
4 56-70	233	218	94%	2.1	848	789	93%	1.0
5 70+	75	69	92%	2.4	694	534	77%	1.4
<b>Deprivation quintile</b>								
1(most deprived)	324	287	89%	1.2	448	412	92%	0.9
2	364	312	86%	1.3	426	392	92%	0.9
3	342	308	90%	1.7	394	357	91%	1.2
4	389	334	86%	1.8	373	341	91%	1.0
5 (least deprived)	312	284	91%	1.9	307	292	92%	1.2

<sup>1</sup>Among patients with any strips dispensed